Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GlycoMimetics, Inc.    GLYC

GLYCOMIMETICS, INC.

(GLYC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GLYCOMIMETICS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

11/06/2020 | 09:43am EST

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2020, GlycoMimetics, Inc. (the "Registrant") issued a press release announcing its financial results for the third quarter ended September 30, 2020. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits


Exhibit
 Number                             Exhibit Description
  99.1       Press Release, dated November 6, 2020, "GlycoMimetics Reports
           Highlights and Financial Results for Third Quarter 2020"

  104      Cover Page Interactive Data File (the cover page XBRL tags are
           embedded within the Inline XBRL document)








                                       2

© Edgar Online, source Glimpses

All news about GLYCOMIMETICS, INC.
01/07GLYCOMIMETICS : Drug Candidate For Acute Myeloid Leukemia Gets Chinese Regulator..
MT
2020GLYCOMIMETICS : New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Si..
BU
2020Roth Capital Adjusts GlycoMimetics' Price Target to $15 From $9, Reiterates B..
MT
2020GLYCOMIMETICS : Uproleselan in Combination with Venetoclax HMA Shown to Break Ch..
AQ
2020GLYCOMIMETICS : ' Uproleselan in Combination With Venetoclax/HMA Shown to Break ..
BU
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
AQ
2020GLYCOMIMETICS : to Present at Two Upcoming Virtual Healthcare Investor Conferenc..
BU
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
AQ
2020GLYCOMIMETICS INC : Results of Operations and Financial Condition, Financial Sta..
AQ
2020GLYCOMIMETICS : Reports Highlights and Financial Results for Third Quarter 2020
BU
More news
Financials (USD)
Sales 2020 8,40 M - -
Net income 2020 -50,5 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,45x
Yield 2020 -
Capitalization 182 M 182 M -
Capi. / Sales 2020 21,7x
Capi. / Sales 2021 -
Nbr of Employees 57
Free-Float 97,8%
Chart GLYCOMIMETICS, INC.
Duration : Period :
GlycoMimetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLYCOMIMETICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 10,50 $
Last Close Price 3,81 $
Spread / Highest target 294%
Spread / Average Target 176%
Spread / Lowest Target -21,3%
EPS Revisions
Managers and Directors
NameTitle
Rachel K. King President, Chief Executive Officer & Director
Timothy R. Pearson Chairman
Brian M. Hahn Chief Financial Officer & Senior Vice President
John L. Magnani Chief Scientific Officer & Senior VP-Research
Helen M. Thackray Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GLYCOMIMETICS, INC.1.33%182
GILEAD SCIENCES, INC.16.70%85 227
VERTEX PHARMACEUTICALS0.15%61 551
WUXI APPTEC CO., LTD.14.44%58 153
REGENERON PHARMACEUTICALS12.25%57 234
BEIGENE, LTD.40.41%33 081